BioAge Labs, Inc. BIOA
4.28 USD -0.43 (-9.13%)
Regular-session close
4.30 +0.02 +0.47%
After hours · Nov 20, 5:35 PM ET
4.24 Day range 4.77
4.28 52-week range 25.10
- YTD
- -67.65%
- 1 year
- -50.17%
News
benzinga.com Citigroup Maintains Buy on Bioage Labs, Lowers Price Target to $20 Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $21 to $20.
seekingalpha.com BioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 Transcript BioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Piper Sandler Maintains Overweight on Bioage Labs, Lowers Price Target to $40 Piper Sandler analyst Yasmeen Rahimi maintains Bioage Labs (NASDAQ:BIOA) with a Overweight and lowers the price target from $73 to $40.
benzinga.com Bioage Labs Q3 EPS $(0.73) Misses $(0.59) Estimate, Sales $298.000K Miss $1.644M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.59) by 23.73 percent. This is a 30.36 percent decrease over losses of…
benzinga.com BioArctic AB Announces Novartis Terminates Their 2025 Option, Collaboration And License Deal; BioArctic To Retain Full $30M Upfront Payment BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered…
